Aung Naing, Professor at MD Anderson Cancer Center, shared on X:
“Grateful to our patients and colleagues for all we have learned from them while working on our review of the immune checkpoint inhibitor journey.
We keep learning to take better care of our patients and improve treatment outcomes.”
Main findings of this study
The study highlights that although immune checkpoint inhibitors (ICIs) have transformed cancer treatment, their effectiveness remains limited by
- immune-related adverse events
- treatment resistance
- insufficient predictive biomarkers.
The authors emphasize the need for more personalized approaches to patient selection and toxicity management.
They discuss phenotype-guided, steroid-sparing strategies to control toxicities while preserving antitumor activity, alongside approaches addressing tumor-intrinsic, microenvironmental, and host-related resistance.
Advances in immune profiling, genomics, and microbiome research may improve prediction of response, toxicity, and clinical outcomes. The review advocates rational combinations and targeted immunomodulation to achieve safer, more durable, patient-centered immunotherapy.
Read the full article.
Title: The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact
Authors: Joud Hajjar, Bettzy Stephen, Ashley E. Aaroe, Mazen M. Aiche, Nagham Al-Zubidi, May Ameri, Kaitlyn E. Aragon, Ivan Darin Carabenciov, Mark S. Chambers, Amina Lateef Chaudhry, Jean M. Connors, Michael A. Davies, Kala Chand Debnath, Saadia A. Faiz, Clifton D. Fuller, Ryan P. Goepfert, Dan S. Gombos, Shruti Gupta, Matthew Hadfield, Katherine A. Hutcheson, Shajedul Islam, Abdullah Jalal, Migara Jayasekera, Khalid A. Jazieh, Aye Khine, Peter Kim, Stephen Y. Lai, Yu Leo Lei, Yuanteng Jeff Li, Svetomir N. Markovic, Holly McMillan, Amy C. Moreno, Fiorinda Muhaj, Marc-Elie Nader, Adegbenga Otun, Omar Pacha, Nicolas L. Palaskas, Anisha B. Patel, Nimisha Patel, Zoe Quandt, Oded Sagiv, Elad Sharon, Malek Shatila, Ajay Sheshadri, Maria E. Suarez-Almazor, Anusha Shirwaikar Thomas, Yinghong Wang, Alex Won, Hao Chi Zhang, Aung Naing
You may also be interested in:
Narjust Florez: Bispecific Antibodies Targeting Two Immune Checkpoints May Boost Antitumor Responses
Can the Tumor’s Own B Cells Reveal the Next Immunotherapy Target?